I

Immunic Therapeutics

66 employees

Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.

Basic info

Industry

biotechnology research

Sectors

Biotechnology

Therapeutics

Medical

Life Science

Date founded

2016

Funding rounds raised

Total raised

$60M

from 17 investors over 17 rounds

I

Immunic Therapeutics raised $60M on October 10, 2022

Investors: Great Point Partners, Logos Global Management, LP, RTW Investments, LP, The Invus Group, Commodore Capital, LP, Parkman Healthcare Partners LLC and Vivo Capital

I

Immunic Therapeutics raised undisclosed on August 1, 2019

Investors: Federal Ministry of Education and Research, Germany

I

Immunic Therapeutics raised $12M on September 5, 2017

Investors: Omega Funds, EQT Life Sciences, Bayern Kapital GmbH and FundPlus

I

Immunic Therapeutics raised $4.3M on February 1, 2017

Investors: BMP Marketing and LSP (Life Sciences Partners)

I

Immunic Therapeutics raised $20M on September 27, 2016

Investors: High-Tech Gründerfonds, Bayern Kapital GmbH and EQT Life Sciences